A randomised 24-week double-blind placebo-controlled trial of tiotropium 18g once daily ( via HandiHaler ) was performed in maintenance therapy-naive patients with forced expiratory volume in 1 s ( FEV1 ) / forced vital capacity ( FVC ) ratio < 0.7 and post-bronchodilator FEV1 50 and < 80 % .